Targeting specific mutations in T cell lymphoma for treatment
Official title: Selective targeting of a Rho GTPase mutant for peripheral T cell lymphoma treatment
Funded at Texas A&m University Health Science Ctr · NIH-10873914 · Data updated 2026-11-12
This study is looking for better ways to treat peripheral T cell lymphoma, an aggressive cancer, by using new technology and existing medications to target specific genetic changes in the disease, with the hope of finding more effective treatments for patients like you.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Texas A&m University Health Science Ctr NIH-funded |
| Lab location | 1 site (College Station, United States) |
| Project start | July 1, 2023 |
| Project end | June 30, 2025 |
| Funding year | 2024 |
| Award (this year) | $168,026 |
| NIH project number | 5R21CA277257-02 |
| Project ID | NIH-10873914 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with peripheral T cell lymphoma who have specific genetic mutations, particularly in TET2 and RHOA.
✕Less likely to help
Patients with other types of lymphomas or those without the targeted genetic mutations may not benefit from this research.
What this research studies
This research focuses on developing targeted therapies for peripheral T cell lymphoma (PTCL), a type of aggressive cancer that arises from T cells. The team aims to create new treatments by utilizing Proteolysis Targeting Chimera (PROTAC) technology and repurposing existing medications to specifically target genetic mutations found in PTCL patients. By studying genetically modified mouse models that mimic the disease, researchers hope to understand how these mutations drive cancer progression and how to effectively reduce tumor growth. This approach is designed to provide a more effective treatment option for patients suffering from this challenging condition.
Why it matters
Potential benefit: If successful, this research could lead to more effective and targeted treatment options for patients with peripheral T cell lymphoma.
How similar studies have gone: Other research has shown promise in targeting specific genetic mutations in cancers, indicating that this approach could be effective.
Where this research is happening
-
Texas A&m University Health Science Ctr
College Station, United States Active
Researchers
- Principal investigator: Zhou, Yubin — Texas A&m University Health Science Ctr
- Study coordinator: Zhou, Yubin
Related research
Other NIH-funded projects on the same topics.
-
CD2-targeted CAR-T therapy for T-cell lymphoma in a multi-center program
A patient-focused overview of a research grant that aims to improve CAR-T cell therapy for T-cell lymphoma by exploring CD2 as a new target and enhancing allogeneic CAR-T safety features.
-
IL-15 and skin-homing CTCL: a targeted approach to curb skin lesions
This grant studies how the inflammatory signal IL-15 drives CTCL T cells to settle in the skin and how blocking this pathway might help patients with this skin-limited leukemia.
-
CD5 CAR-T therapy for T-cell lymphoma shows promise in a multi-center trial
A phase 2 study tests a CD5-targeted CAR-T cell therapy in people with relapsed or refractory T-cell lymphoma to see if it can improve outcomes.
-
Staphylococcus aureus and CTCL: How skin bacteria may drive a blood cancer
A doctor-scientist team is studying how certain strains of Staphylococcus aureus on the skin might influence the development and progression of cutaneous T-cell lymphoma (CTCL) in patients.
-
How a rare intestinal T‑cell lymphoma begins
This project will test whether losing the SETD2 gene and turning on certain cancer genes causes a rare intestinal T‑cell lymphoma and makes it more sensitive to chemotherapy for people with MEITL.
-
CD5 CAR‑T treatment for relapsed or hard‑to‑treat T‑cell lymphoma
This project is trying CD5‑targeted CAR‑T cell therapy, including faster off‑the‑shelf products, to help people with relapsed or refractory T‑cell lymphoma get better responses.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.